Implementing Artificial Intelligence Into the Neuro-Oncology Field

News
Video

AI has the potential to change practice patterns, improve imaging, and inform treatment planning for patients with brain tumors.

Artificial intelligence (AI) is poised to gradually break its way into the neuro-oncology world, according to Nicholas Blondin, MD.AI and machine learning may revolutionize how clinicians diagnose, treat, and manage primary and metastatic brain cancers.

Blondin, associate professor of Clinical Neurology at Yale School of Medicine, spoke with CancerNetwork® about the use of AI in this setting. He talked about the potential of AI to improve the accuracy and speed of brain tumor diagnosis, potentially identifying subtle patterns that may be missed by the human eye.

Of note, Blondin addressed the challenges and ethical considerations associated with implementing AI in clinical practice, including data privacy. Ultimately, he emphasized maintaining doctor-patient relationships as AI tools continue to advance in the neuro-oncology field.

Transcript:

In some ways, this is an exciting time with the rise of AI and machine learning. There are privacy concerns about the use of AI in health care settings. On the other hand, there is a lot of opportunity for AI to help us better interpret MRIs and better understand treatment options. In the last few months, I’ve seen some reports of AI being used to those ends. There was a recent report of AI use in pediatric brain cancer management, where it seemed like some useful conclusions were drawn from that.

It’s still very early days [for AI]. In my actual practice, I’ve just started using AI to try to understand treatment options better for patients or build out treatment programs. [AI] is going to advance a lot in the next few years. Ultimately, doing this line of work of neuro-oncology and [and being a doctor is about having the] doctor-patient relationship [and] having a therapeutic alliance. It’ll be, hopefully, a very useful tool for me as a physician to help take better care of my patients. Also, I hope my patients utilize AI as well and come up with their own concepts and ideas and bring them to me [so] we can discuss and learn things together. Hopefully, this will all just move the field forward on how patients have better outcomes.

Recent Videos
A consolidated database may allow providers to access information on a patient’s prior treatments and genetic abnormalities all in 1 place.
Experts at Yale Cancer Center highlight ongoing trials intended to improve outcomes across mantle cell lymphoma, T-cell lymphoma, and other populations.
Yale’s COPPER Center aims to address disparities and out-of-pocket costs for patients, thereby improving the delivery of complex cancer treatment.
A study presented at ASTRO 2025 evaluated the feasibility of using a unified cancer database to consolidate information gathered across 14 institutions.
Non-Hodgkin lymphoma and other indolent forms of disease may require sequencing new treatments for years or decades, said Scott Huntington, MD, MPH, MSc.
Fixed-duration therapy may be more suitable for younger patients, while continuous therapy may benefit those who are older with more comorbidities.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ESMO Annual Congress, from hot topics and emerging trends to travel recommendations.
Andrezj Jakubowiak, MD, PhD, prioritizes KRd-based regimens for the treatment of high-risk newly diagnosed disease in the post-transplant setting.
A new clinical trial aims to offer a novel allogenic CAR T-cell product for patients with lymphoma closer to home.
Related Content